

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM

M.A. Nauck¹, D. Wollschläger², J. Werner², J.J. Holst³, C. Ørskov³, W. Creutzfeldt⁴, B. Willms²

¹ Department of Medicine, Ruhr-University Bochum, Knappschafts-Krankenhaus, Bochum, Germany

² Fachklinik für Diabetes und Stoffwechselkrankheiten, Bad Lauterberg, Germany

³ Departments of Anatomy and Physiology, Panum Institute, University of Copenhagen, Denmark

⁴ Division of Gastroenterology and Endocrinology, Department of Medicine, Georg-August-University, Göttingen, Germany

Summary Intravenous glucagon-like peptide (GLP)-1 [7–36 amide] can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients. Since this is no form for routine therapeutic administration, effects of subcutaneous GLP-1 at a high dose (1.5 nmol/kg body weight) were examined. Three groups of 8, 9 and 7 patients (61 ± 7 , 61 ± 9 , 50 ± 11 years; BMI 29.5 ± 2.5 , 26.1 ± 2.3 , 28.0 ± 4.2 kg/m²; HbA_{1c} 11.3 ± 1.5 , 9.9 ± 1.0 , $10.6 \pm 0.7\%$) were examined: after a single subcutaneous injection of 1.5 nmol/kg GLP [7–36 amide]; after repeated subcutaneous injections (0 and 120 min) in fasting patients; after a single, subcutaneous injection 30 min before a liquid test meal (amino acids 8%, and sucrose 50 g in 400 ml), all compared with a placebo. Glucose (glucose oxidase), insulin, C-peptide, GLP-1 and glucagon (specific immunoassays) were measured. Gastric emptying was assessed with the indicator-dilution method and phenol red. Repeated measures ANOVA was used for statistical analysis. GLP-1 injection led to a short-lived increment in GLP-1 concentrations (peak at 30–60 min, then return to basal levels after 90–120 min). Each GLP-1 injection stimulated insulin (insulin, C-peptide, $p < 0.0001$, respectively) and inhibited glucagon secretion ($p < 0.0001$). In fasting patients the repeated administration of GLP-1

normalized plasma glucose (5.8 ± 0.4 mmol/l after 240 min vs 8.2 ± 0.7 mmol/l after a single dose, $p = 0.0065$). With the meal, subcutaneous GLP-1 led to a complete cessation of gastric emptying for 30–45 min ($p < 0.0001$ statistically different from placebo) followed by emptying at a normal rate. As a consequence, integrated incremental glucose responses were reduced by 40% ($p = 0.051$). In conclusion, subcutaneous GLP-1 [7–36 amide] has similar effects in NIDDM patients as an intravenous infusion. Preparations with retarded release of GLP-1 would appear more suitable for therapeutic purposes because elevation of GLP-1 concentrations for 4 rather than 2 h (repeated doses) normalized fasting plasma glucose better. In the short term, there appears to be no tachyphylaxis, since insulin stimulation and glucagon suppression were similar upon repeated administrations of GLP-1 [7–36 amide]. It may be easier to influence fasting hyperglycaemia by GLP-1 than to reduce meal-related increments in glycaemia. [Diabetologia (1996) 39: 1546–1553]

Keywords GLP-1 [7–36 amide], incretin, insulin, glucagon, pharmacokinetics.

Corresponding author: Priv.-Doz. Dr. med. M. Nauck, Department of Medicine, Ruhr-University Bochum, Knappschafts-Krankenhaus, In der Schornau 23–25, D-44892 Bochum, Germany

Abbreviations: BMI, Body mass index; EDTA, ethylene diamine tetra-acetic acid; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; RM-ANOVA, repeated mea-

Glucagon-like peptide 1 (GLP-1) [7–36 amide] is an insulinotropic hormone secreted from enteroglucagon-producing L cells in the lower gut, i.e. the ileum and colon/rectum [1, 2]. GLP-1 [7–36 amide], together with gastric inhibitory polypeptide (GIP) from the upper gut, acts as a physiological incretin hormone [3, 4]. In pharmacological concentrations,

Table 1. Characteristics of NIDDM patients studied

| Parameter | Study A Fasting patients Single dose | Study B Fasting patients Repeated dose | Study C Liquid meal Single dose | Significance ANOVA (<i>p</i> -value) |
|--------------------------------------|--|--|---------------------------------------|---|
| Sex (male/female) | 5/3 | 4/5 | 3/4 | 0.69 |
| Age (years) | 61 ± 7 | 61 ± 9 | 50 ± 11 | 0.03 |
| Body mass index (kg/m ²) | 29.5 ± 2.5 | 26.1 ± 2.3 | 28.0 ± 4.2 | 0.096 |
| Diabetes duration (years) | 9 ± 3 | 11 ± 7 | 10 ± 4 | 0.59 |
| HbA _{1c} (%) | 11.3 ± 1.5 | 9.9 ± 1.0 | 10.6 ± 0.7 | 0.054 |
| Diet (kCal/day) | 1429 ± 262 | 1538 ± 348 | 1416 ± 253 | 0.66 |
| Glibenclamide (mg/day) | 9.6 ± 2.5 | 10.5 ± 0 | 10.5 ± 0 | 0.39 |
| Metformin (yes/no) | 1/7 | 2/7 | 6/1 | 0.007 |
| Acarbose (yes/no) | 1/7 | 0/9 | 0/7 | 0.35 |
| RR _{systolic} (mmHg) | 162 ± 28 | 138 ± 19 | 136 ± 12 | 0.043 |
| RR _{diastolic} (mmHg) | 94 ± 16 | 72 ± 13 | 82 ± 11 | 0.012 |

Data are mean ± SD

non-insulin-dependent diabetic (NIDDM) patients [5, 6]. By these mechanisms, plasma glucose was normalized within 3–4 h by i. v. GLP-1 [7–36 amide] in NIDDM patients with secondary failure of sulphonylurea treatment [7]. Therefore, GLP-1 [7–36 amide] or GLP-1 [7–37] (which has an identical action profile in rats [8], normal humans [9] and NIDDM patients [10]) has been suggested for use in the therapy of NIDDM patients [5–7, 10, 11]. However, a mode of administration has to be sought that both makes use of the potential to normalize glycaemia in NIDDM patients [7, 10] and that will be acceptable when compared with other current therapy. One obvious way is the s. c. administration of this peptide hormone. Limited experience using small doses of GLP-1 [7–36 amide] have been reported by Gutniak et al. [12]. However, they only used it to reduce postprandial glycaemic excursions. GLP-1 [7–36 amide] was injected shortly before the ingestion of a meal, and the effects noted were smaller in comparison to the normalization of fasting hyperglycaemia that can be achieved by i. v. GLP-1 [7–36 amide] in NIDDM patients [6, 10]. Since i. v. GLP-1 [7–36 amide] profoundly influences fasting hyperglycaemia in NIDDM patients [7, 10], it was the aim to also examine the effect of s. c. GLP-1 in fasting patients, and to compare it to a preprandial administration. The amount administered in the present study was the maximum dose that was free of severe side-effects in young, healthy volunteers [13]. Preliminary results have been communicated in abstract form [14].

Subjects, materials and methods

Study protocol. The study protocols were approved by the ethics committee of the medical faculty of the Georg-August University, Göttingen, prior to the study. Written, informed consent was obtained from all participants.

unsatisfactory metabolic control. Their characteristics are shown in Table 1. All were treated with diet and oral agents (sulphonylurea in all, plus acarbose or metformin in some). Diabetes, on average, had been diagnosed approximately 10 years earlier. Metabolic control at the time of the study, as indicated by HbA_{1c} values of 10–11% (normal: 4.3–6.1%), was unsatisfactory. Most patients were slightly obese.

All patients were studied on two occasions; in randomized order, in a single-blind fashion, placebo (0.9% NaCl with 1% human serum albumin) or GLP-1 [7–36 amide] in a dose of 1.5 nmol/kg body weight was administered in the morning after an overnight fast as a single or repeated dose. Anti-diabetic medication (Table 1) was given until the night before the first experiment. Between the experiments, 1 day with a regular eating and treatment schedule (including all drugs) was allowed.

Three protocols were compared: *Study A* examined the effect of a single s. c. injection of GLP-1 [7–36 amide] (administered at time 0 min) in fasting NIDDM patients followed for 240 min. *Study B* examined the effect of a repeated s. c. injection of GLP-1 [7–36 amide] (administered at time 0 and 120 min) in fasting NIDDM patients followed for 240 min. *Study C* examined effects of a preprandial single s. c. injection of GLP-1 [7–36 amide] (administered at time –30 min) in NIDDM patients. At time 0 min, a liquid mixed meal made up of a commercially available amino acid solution (Aminosteril N-Hepa 8%; Fresenius AG, Bad Homburg, Germany) and sucrose (50 g per 400 ml) was administered via a nasogastric tube. Results were observed over 240 min.

Peptides. Synthetic GLP-1 [7–36 amide] was purchased from Saxon Biochemicals GmbH, Hannover, Germany (PGAS 242). The peptide was dissolved in 0.9% NaCl containing 1% human serum albumin (Merieux, Norderstedt, Germany), filtered through 0.2 µm nitrocellulose filters (Millipore, Bedford, Mass., USA) and stored frozen at –30 °C as previously described [4, 5, 7]. Net peptide content rather than gross weight was used for dose calculations. High performance liquid chromatography profiles (provided by the manufacturer) showed that the preparation was more than 99% pure (single peak coeluting with appropriate standards). Samples were analysed for bacterial growth (standard culture techniques) and for pyrogens (Limulus ameocyte lysate endo-LAL, Chromogenix AB, Mölndal, Sweden). No bacterial contamination was detected. Endotoxin concentrations in the GLP-1

Experimental procedures. One forearm vein was punctured with a teflon cannula (Moskito 123, 18 gauge; Vygon, Aachen, Germany), and kept patent using 0.9% NaCl.

In experiments with fasting NIDDM patients, after drawing basal blood specimens, at 0 min, GLP-1 [7–36 amide] was administered s. c. into the periumbilical region. The injected volume was 1 ml per 85 kg body weight. In study B, at 120 min the subcutaneous injection of GLP-1 [7–36 amide] was repeated.

Blood specimens. Blood was drawn into heparinized tubes (immunoreactive [IR] insulin and C-peptide measurements). A sample was stored in NaF (Microvette CB 300; Sarstedt, Nümbrecht, Germany) for the measurement of glucose. For glucagon and GLP-1 [7–36 amide] measurements, blood was drawn into tubes containing ethylene diamine tetra-acetic acid (EDTA) and aprotinin (Trasylol; 20 000 kallikrein inhibitor units/ml, 200 µl per 10 ml blood; Bayer AG, Leverkusen, Germany). After centrifugation, plasma for hormone analyses was kept frozen at -30°C .

Gastric emptying. In study C, before the start of the experiments, a nasogastric tube (Freka-Ernährungssonde, 120 cm, CH 12, Fresenius AG) was placed and tape-fixed with the tip approximately 55 cm from the nostrils. Gastric juice was aspirated and an acid pH was ascertained using pH-sensitive lackmus paper. The gastric lumen was washed with 100 ml tap water warmed to 37°C . If instilled water could not be completely aspirated, the position of the tube was adjusted to allow a near-complete aspiration of instilled fluid. The patients were in a semi-recumbent position, with the upper body 45° upright. At -30 min, GLP-1 [7–36 amide] was administered s. c., and at 0 min, the liquid meal (warmed to 37°C) was instilled into the stomach. Previous studies had indicated peak plasma concentrations around 30 min after s. c. injection of GLP-1 [7–36 amide] [13]. The meal consisted of 32 g mixed amino acids (131 kCal = 40% of total caloric content) and 50 g sucrose (196 kCal = 60%). Total energy content was 327 kCal (energy density 0.82 kCal/ml) [15, 16].

Gastric emptying was determined exactly as in a previous study testing intravenously infused GLP-1 [7–36 amide] in a similar group of NIDDM patients [15], by a double-sampling dye dilution technique using phenol red (Merck AG, Darmstadt, Germany), according to George [17], with modifications introduced to reduce the measurement error by Hurwitz et al. [18]. In principle, at all time-points chosen to measure gastric volume, a known amount of the non-absorbable phenol red dye was added to the translucent test meal in a volume of 5 to 15 ml. After thorough mixing with gastric contents for approximately 2 min, a gastric sample was drawn, and the resulting step-up in phenol red concentrations was determined photometrically. Increasing amounts of phenol red were used as the experiments proceeded to obtain clearly measurable increments in optical density also in the presence of previously instilled phenol red [18]. In vitro, this method measured gastric volume with an accuracy of less than 6% (coefficient of variation).

Laboratory determinations. Glucose was measured using a glucose oxidase method with a Glucose Analyser 2 (Beckman Instruments, Munich, Germany). Plasma IR-insulin and C-peptide were determined using commercial immunoassay kits. Insulin was measured using an insulin microparticle enzyme immunoassay (MEIA) IMx Insulin, Abbott Laboratories, Wiesbaden, Germany, which shows a correlation coefficient 0.982

were less than 4.0%. C-peptide was measured using C-peptide antibody-coated microtitre wells (C-peptide MTPL EIA) from DRG Instruments GmbH, (Marburg, Germany). Human insulin and C-peptide were used as standard.

IR-GLP-1 was determined in ethanol-extracted plasma as previously described [19], using antiserum 89 390 (final dilution 1:150 000) and synthetic GLP-1 [7–36 amide] for tracer preparation and as standard. Recovery of GLP-1 [7–36 amide] standards after alcohol extraction was $75 \pm 8\%$. The experimental detection limit (2 standard deviations over samples not containing GLP-1 [7–36 amide]) was less than 5 pmol/l. Antiserum 89 390 binds proglucagon-derived peptides containing the amidated carboxy-terminus of GLP-1 [7–36 amide], thereby being relatively specific for GLP-1 [7–36 amide] [20]. Plasma samples with expected high concentrations were diluted 1:10 with assay buffer before analysis.

Pancreatic glucagon was assayed in ethanol-extracted plasma using antibody 4305 [21]. GIP was determined using antiserum R 65 and synthetic human GIP for the preparation of standards and ^{125}I GIP tracer (purified by HPLC) as described by Krarup et al. [22]. GIP was not measured in the experiments with fasting patients, since GLP-1 [7–36 amide] does not stimulate GIP release in humans [4, 5].

Each patient's set of plasma samples was assayed at the same time to avoid errors due to inter-assay variation.

Symptoms. During the experiments, the volunteers were observed and frequently asked about their state of well-being. Their answers were recorded using an open questionnaire.

Statistical analysis

Subject characteristics are reported as mean \pm SD, experimental results are reported as mean \pm SEM. Integration was carried out according to the trapezoidal rule, separately calculating increments over and decrements below mean baseline values. Metabolic clearance rates were calculated as the dose of s. c. GLP-1 [7–36 amide], divided by the integrated incremental response. Significances of differences were tested using repeated measurement analysis of variance (RM-ANOVA; NCSS Version 5.01, Kaysville, Utah, USA). If a significant interaction of treatment and time was documented ($p < 0.05$), values at single time points were compared by Student's *t*-test (paired analyses; GLP-1 [7–36 amide] vs placebo). For the analysis of time courses one-way ANOVA was used, followed by *t*-tests (vs mean basal values), if indicated. For contingency table analysis, a chi square-test was used. A two-sided *p*-value less than 0.05 was taken to indicate significant differences.

Results

All patients were hyperglycaemic at the start of the experiments (mean plasma glucose concentrations over 11 mmol/l; Figs. 1 and 2).

Study A. A single s. c. administration of GLP-1 [7–36 amide] reduced plasma glucose concentrations by approximately 2–3 mmol/l (Fig. 1A), mainly during the initial 120 min, but the effect was maintained throughout the 240-min period. Insulin (Fig. 1B) and C-peptide (Fig. 1C) were stimulated (peak 30 min af




Fig. 1. A-H. Effects of single (*left panels, A-D*) and repeated (*right panels, E-H*) s.c. administrations of GLP-1 [7-36 amide] (1.5 nmol/kg body weight) on plasma glucose (**A, E**), insulin (**B, F**), C-peptide (**C, G**), and glucagon (**D, H**) concentrations in NIDDM patients. Arrows indicate time point of GLP-1 [7-36 amide] administration. Experiments with GLP-1 [7-36 amide] (●) or placebo (○). *P*-values indicate significance of interaction of experiment (GLP-1 [7-36 amide] vs placebo) and time. *: Differences at specific time points (*t*-test, *p* < 0.05)

but transiently, and returned to baseline values after 90–120 (insulin) and 150–180 (C-peptide) min.

GLP-1 [7-36 amide] concentrations reached peak values of around 400–550 pmol/l 30–60 min after s.c. administrations of 1.5 nmol/kg body weight GLP-1 [7-36 amide] (Fig. 2A) and returned to baseline values within 120–180 min after injection.

Glucagon concentrations were transiently, but significantly (*p* < 0.0001) suppressed during 90 min after GLP-1 [7-36 amide] administration (Fig. 1D).

Study B. In contrast to the single s.c. administration of GLP-1 [7-36 amide], the repeated administration (two doses administered at 0 and 120 min) resulted in a step-wise normalization of fasting glycaemia in




Fig. 2. A-C. Effects of single (**A**) and repeated (**B**) s.c. administrations of GLP-1 [7-36 amide] (1.5 nmol/kg body weight) in the fasting state, and of single (**C**) s.c. administrations of GLP-1 [7-36 amide] administered before a liquid test meal on plasma GLP-1 [7-36 amide] concentrations in NIDDM patients. Arrows indicate time point of GLP-1 [7-36 amide] administration and of the intragastric installation of the meal. Experiments with GLP-1 [7-36 amide] (●) or placebo (○). *P*-values indicate significance for the interaction of experiment (GLP-1 [7-36 amide] vs placebo) and time. *: Differences at specific time points (*t*-test, *p* < 0.05)

The plasma glucose reached at the end of the experiment was significantly lower (5.8 ± 0.4 mmol/l) than after the single dose (8.2 ± 0.7 mmol/l; *p* = 0.0065, *t*-test), while there was no significant difference in the integrated decremental response.

Insulin and C-peptide showed a second increment after the administration of GLP-1 [7-36 amide] at 120 min (Fig. 1F and G), which made the overall insulin and C-peptide responses greater (*p* < 0.05 for both) than in the experiment with single doses of GLP-1 [7-36 amide] (Fig. 1B and C). The responses of insulin and C-peptide to the second injection of GLP-1 [7-36 amide] were similar in magnitude to




Fig. 3. A–D. Effects of a single s.c. administration of GLP-1 [7-36 amide] (1.5 nmol/kg body weight) on plasma glucose (A), insulin (B), C-peptide (C), and glucagon (D) concentrations in NIDDM patients before and after feeding a liquid test meal. Arrows indicate the time point of GLP-1 [7-36 amide] administration and of the intragastric instillation of the meal. Experiments with GLP-1 [7-36 amide] (●) or placebo (○). *P*-values indicate significance for the interaction of experiment (GLP-1 [7-36 amide] vs placebo) and time. *: Differences at specific time points (*t*-test, $p < 0.05$)

G; $p = 0.99$ and 0.48 for integrated incremental insulin and C-peptide responses, respectively), although plasma glucose concentrations had already been lowered in response to the first injection (Fig. 1E).

GLP-1 [7-36 amide] plasma values showed a sig-




Fig. 4. Effects of single s.c. administrations of GLP-1 [7-36 amide] (1.5 nmol/kg body weight) on gastric emptying rates after the intragastric instillation of a liquid test meal in NIDDM patients. Arrow indicates time point of GLP-1 [7-36 amide] administration. Experiments with GLP-1 [7-36 amide] (●) or placebo (○). *P*-values indicate the significance for the interaction of experiment (GLP-1 [7-36 amide] vs placebo) and time. *: Differences at specific time points (*t*-test, $p < 0.05$)

concentrations were reduced significantly ($p < 0.0001$) 30 min after each administration (Fig. 1H). The reduction in glucagon was similar after the first and second injection ($p = 0.51$). However, the overall reduction in glucagon (integrated decremental responses) was not significantly different from experiments with a single dose of GLP-1 [7-36 amide].

Study C. Intragastric instillation of a liquid mixed meal containing 50 g sucrose, together with the administration of placebo, raised mean plasma glucose concentrations to over 15 mmol/l (Fig. 3A). However, with GLP-1 [7-36 amide] administered s.c. 30 min before the meal, plasma glucose values were lowered rather than elevated during the initial 30–45 min after the meal, with a later rise that was attenuated in comparison with placebo studies (Fig. 3A). The rise in glycaemia over basal values (integrated incremental responses), however, was only reduced from 529.2 ± 54.3 mmol \cdot l $^{-1}$ \cdot min (placebo) to 318.6 ± 106.7 (GLP-1 [7-36 amide]), which was only of borderline significance ($p = 0.051$). There was a short increment in insulin (Fig. 3B) and C-peptide (Fig. 3C) plasma concentrations during the initial 30 min after GLP-1 [7-36 amide] administration (i.e. before the meal was given), but later insulin and C-peptide curves were similar to those with the placebo. Due to the initial peak in insulin and C-peptide (Fig. 3B and C), the overall integrated incremental insulin (21.6 ± 4.7 vs 15.9 ± 3.8 nmol \cdot l $^{-1}$ \cdot min, $p = 0.0032$) and C-peptide (139.9 ± 20.6 vs 97.9 ± 20.1 nmol \cdot l $^{-1}$ \cdot min, $p = 0.0054$) response was greater with s.c. GLP-1 [7-36 amide].

The time course of GLP-1 [7-36 amide] plasma concentrations (Fig. 2C) after s.c. injection was similar to that described in fasting patients (Fig. 2A and B, Table 2). There was a significant increment in GLP-1

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.